Allogenetic Bone Marrow Derived Mesenchymal Stem Cell Transplantation for the Treatment of Prostate Cancer in Murine Model

ZHANG Yi-nan,GUO Jian-ming,JIN Xun-bo,WANG Guo-min,WANG Li,TANG Hui-qing
DOI: https://doi.org/10.3969/j.issn.1674-7410.2010.04.002
2010-01-01
Abstract:Objective To explore the possible graft versus tumor(GVT)effects induced by allogenetic bone marrow derived mesenchymal stem cell(MSC)transplantation in murine prostate cancer model.Methods Bone marrow cells were cultured and purified by adherent method to the fourth generation.The MSCs were then identified by flow cytometry for CD44 positive cells and oil red stain for the differentiated fat cells.Following nonmye-loablative regimens consisted of fludarabine(30mg/m~2,-d~(1-5))and cyclophosphamide(300mg/m~2,-d~(1-3)), C57BL mice bearing RM-1(2×10~6 each)tumors underwent an allogeneic bone marrow MSCs(2×10~6 each) transplantation and bone marrow cells(5×10~6 each)and spleen cells(1×10~7 each)transplantation from BALB/ c donors through the tail veins.The tumor volumes and survival time were recorded,and then compared with the control group.Results The percentage of CD44 positive cells in the fourth generation was 84.29%,and the oil red stain proved the existence of differentiated fat cells.Comparing with the control group,allogenetic bone marrow derived MSC transplantation inhibited the growth of the tumors and prolonged the recipients' survival time significantly(P=0.047 and 0.00001,respectively).Conclusions Allogenetic bone marrow derived MSC transplantation inhibited the growth of the tumors and prolonged the recipients' survival time significantly,which suggesting its promising future as a functional tumor-specific delivery vehicle.
What problem does this paper attempt to address?